Source: Annual Congress 2005 - In vivo - approaches to lung injury
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. Fujimoto, E. C. Gabazza, M. Nagashima, J. Morser, H. Nakahara, Y. Nishii, C. N. D‘Alessandro-Gabazza, H. Kobayashi, O. Taguchi (Tsu, Japan; Richmond, United States Of America). Thrombin-activatable fibrinolysis inhibitor deficiency attenuates bleomycin-induced pulmonary fibrosis. Eur Respir J 2005; 26: Suppl. 49, 3023

Member's Comments

No comment yet.

Related content which might interest you: The CDK4/6 inhibitor, palbociclib intensifies pulmonary inflammation in bleomycin-induced lung fibrosis Source: Virtual Congress 2020 – Novel immunopathological mechanisms of lung disease: knowledge from translational studies Year: 2020 Effects of elastase inhibitor on the epithelial cell apoptosis in bleomycin-induced pulmonary fibrosis Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology? Year: 2008 Role of thrombin-activatable fibrinolysis inhibitor in lipopolysaccharide-induced acute lung injury Source: Annual Congress 2011 - Experimental modulation of airway inflammation Year: 2011 A neutrophil elastase inhibitor prevents bleomycin-induced pulmonary fibrosis in mice Source: Eur Respir J 2012; 40: 1475-1482 Year: 2012 Effect of NF-?B inhibitor IMD-1041 on BLM-induced pulmonary fibrosis in mice Source: International Congress 2017 – Lung fibrosis: basic science Year: 2017 The PDE4 inhibitor roflumilast reduced bleomycin-induced pulmonary fibrotic and vascular remodeling in mice in vivo Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008 HSP47siRNA targeting to myofibroblasts attenuates bleomycin-induced pulmonary fibrosis Source: Annual Congress 2012 - Interstitial lung disease: from bench to bedside Year: 2012 Antithrombin plus alpha–1 protease inhibitor does not affect pulmonary inflammation and coagulation in a ‘double-hit’ lung injury model Source: International Congress 2018 – Preclinical and clinical studies of critical illness Year: 2018 PD98059 attenuates the development of bleomycin-induced lung injury and fibrosis Source: Annual Congress 2010 - Regulation of airway pharmacology Year: 2010 Neutrophil elastase is necessary for increases in active TGF-β in bleomycin-induced pulmonary fibrosis Source: Eur Respir J 2001; 18: Suppl. 33, 199s Year: 2001 Intraalveolar levels of tenascin C and thrombin-activatable fibrinolysis inhibitor in interstitial lung diseases Source: Eur Respir J 2003; 22: Suppl. 45, 83s Year: 2003 Rho-kinase inhibitor ameliorates bleomycin-induced chronic lung injury in neonatal rats Source: Annual Congress 2011 - Issues in paediatric and neonatal intensive care Year: 2011 Metformin attenuates bleomycin-induced pulmonary fibrosis in mice via IGF-1 suppression Source: International Congress 2018 – Novel insights in the basic and translational research on idiopathic interstitial pneumonias Year: 2018 Antifibrotic effects of Lck inhibition on bleomycin-induced pulmonary fibrosis in mice Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019 Effect of fasudil on the bleomycin-induced pulmonary fibrosis and hypertension in mice Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms Year: 2012 Aminoguanidine attenuates bleomycin-induced pulmonary fibrosis in rats through inhibition of heat shock protein 47 and TGF-β1 expression Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008 PAR-2 antagonist inhibits bleomycin-induced lung fibrosis. Source: International Congress 2019 – Extracellular matrix formation and remodelling in physiology and disease Year: 2019 Increased intraalveolar levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with interstitial lung disease Source: Eur Respir J 2002; 20: Suppl. 38, 586s Year: 2002 Inhibition of the Arp2/3 complex inhibits lung myofibroblast differentiation in vitro and attenuates bleomycin-induced pulmonary fibrosis in mice Source: International Congress 2019 – Extracellular matrix formation and remodelling in physiology and disease Year: 2019 ACE2 activation improves pulmonary endothelial function and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011